Preferential expression of myelencephalon-specific protease by oligodendrocytes of the adult rat spinal cord white matter

GLIA

Volumn 30, Issue 3, 2000, Pages 219-230

  Scarisbrick, Isobel A ^a,c   Asakura, Kuniko ^a   Blaber, Sachiko ^b   Blaber, Michael ^b   Isackson, Paul J ^a   Bieto, Tom ^a   Rodriguez, Moses ^a   Windebank, Anthony J ^a  

^a MAYO CLINIC   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

Author keywords

Astrocyte; Microglia; Multiple sclerosis; Myelin; Oligodendrocyte; Serine protease

Indexed keywords

ANTIBODY SPECIFICITY; ASTROCYTE; CELL GROWTH; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME SYNTHESIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAINIC ACID; MESSENGER RNA; MONOCLONAL ANTIBODY; MYELENCEPHALON SPECIFIC PROTEASE; NERVE FIBER; OLIGODENDROGLIA; WHITE MATTER;

ANIMALS; ASTROCYTES; CELLS, CULTURED; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNOHISTOCHEMISTRY; MALE; MYELIN SHEATH; OLIGODENDROGLIA; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SPINAL CORD;

EID: 0034016029     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1136(200005)30:3<219::AID-GLIA2>3.0.CO;2-2     Document Type: Article

References (51)

1. Alvord EC, Hruby S, Sires LR. 1979. Degradation of myelin basic protein by cerebrospinal fluid: preservation of antigenic determinants under physiological conditions. Ann Neurol 6:474-482.
2. Asakura K, Miller DJ, Murray K, Bansal R, Pfeiffer SE, Rodriguez M. 1996. Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes. J Neurosci Res 43:273-281.
3. Brosnan CF, Cammer W, Norton WT, Bloom B. 1980. Protease inhibitors suppress the development of experimental allergic encephalomyelitis. Nature 285:235-237.
4. Cammer W, Bloom BR, Norton WT, Gordon S. 1978. Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: a possible mechanism of inflammatory demyelination. Proc Natl Acad Sci USA 75:1554-1558.
5. Cammer W, Brosnan CF, Basile C, Bloom BR, Norton WT. 1986. Complement potentiates the degradation of myelin proteins by plasmin: implications for a mechanism of inflammatory demyelination. Brain Res 364:91-101.
6. Cuzner ML, Davison AN, Rudge P. 1978. Proteolytic enzyme activity of blood leukocytes and CSF in multiple sclerosis. Ann Neurol 4:337-44.
7. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, Newcombe J. 1996. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 55:1194-1204.
8. Falekas de St. Groth S, Scheidegger D. 1980. Production of monoclonal antibodies: strategy and tactics. J Immunol Methods 35:1-21.
9. Friedman B, Hockfield S, Black JA, Woodruff KA, Waxman SG. 1989. In situ demonstration of mature oligodendrocytes and their processes: an immunocytochemical study with a new monoclonal antibody, Rip. Glia 2:380-390.
10. Gijbels K, Masure S, Carton H, Opdenakker G. 1992. Gelatinase in cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41:29-34.
11. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. 1993. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 36:432-440.
12. Gijbels K, Galardy RE, Steinman L. 1994. Reversal of experimental allergic encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94:2177-2182.
13. Hewson AK, Smith T, Leonard JP, Cuzner ML. 1995. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflammation Res 44:345-349.
14. Hughes SM, Cho M, Karsch-Mizrachi I, Travis M, Silberstein L, Leinwand LA, Blau HM. 1993. Three slow myosin heavy chains sequentially expressed in developing mammalian skeletal muscle. Dev Biol 158:183-199.
15. Krystosek A, Seeds NW. 1981a. Plasminogen activator release at the neuronal growth cone. Science 213:1532-1534.
16. Krystosek A, Seeds NW. 1981b. Plasminogen activator secretion by granule neurons in cultures of developing cerebellum. Proc Natl Acad Sci USA 78:7810-7814.
17. Liu Y, Fields RD, Festoff BW, Nelson PG. 1994a. Proteolytic activity of thrombin is required for electrical activity-dependent synapse reduction. Proc Natl Acad Sci USA 91:10300-10304.
18. Liu Y, Fields RD, Fitzgerald S, Festoff BW, Nelson PG. 1994b. Proteolytic activity, synapse elimination, and the Hebb synapse. J Neurobiol 25:325-335.
19. Luke Y, Oh S, Larsen PH, Drekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW. 1999. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 19:8486-8475.
20. Marks N, Grynbaum A, Lajtha A. 1976. The breakdown of myelin-bound proteins by intra- and extracellular proteases. Neurochem Res 1:93.
21. McCarthy KD, De Vellis J. 1980. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85:890-902.
22. Monard D. 1988. Cell-derived proteases and protease inhibitors as regulators of neurite outgrowth. Trends Neurosci 11:541-544.
23. Moonen G, Grau-Wagemans M-P, Selack I. 1982. Plasminogen activator-plasmin system and neuronal migration. Nature 298:753-755.
24. Nandon NL, Duncan ID. 1995. Gene expression and oligodendrocyte development in the myelin deficient rat. J Neurosci Res 41:96-104.
25. Norga K, Paemen L, Masure S, Dillen C, Heremans H, Billiau A, Carton H, Cuzner L, Olsson T, Van Damme J, Opdenakker G. 1995. Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Inflammation Res 44:529-534.
26. Opdenakker G, Masure S, Grillet B, Van Damme J. 1991. Cytokine-mediated regulation of human leukocyte gelatinases and their role in arthritis. Lymphokine Cytokine Res 10:317-324.
27. Paemen L, Olsson T, Soderstrom M, Damme JV, Opdenakker G. 1994. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol 1:55-63.
28. Pittman RN, Ivins JK, Buettner HM. 1989a. Neuronal plasminogen activators: cell surface binding site and involvement in neurite outgrowth. J Neurosci 9:4269-4286.
29. 2+-dependent metalloproteinase activity. Dev Neurosci 11:41-51.
30. Pittman RN, Hynicka WP, Hunter M. 1992. Proteases as potential agents for augmenting axon regeneration. In: Lam DM-K, editor. Regeneration and plasticity in the visual system. Boston: MIT. p 79-95.
31. Prayoonwiwat N, Rodriguez M. 1993. The potential for oligodendrocyte proliferation during demyelinating disease. J Neuropathol Exp Neurol 52:55-63.
32. Proost P, Van Damme J, Opdenakker G. 1993. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 192:1175-1781.
33. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. 1993 Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 361:453-457.
34. Rodriguez M, Quddus J. 1986. Effect of cyclosporin A, silica quartz dust, and protease inhibitors on virus-induced demyelination. J Immunol 13:159-174.
35. Rouleau A, Dimitriadou V, Trung Tuong MD, Newlands GFJ, Miller HRP, Schwartz J-C, Garbarg M. 1997. Mast cell specific proteases in rat brain: changes in rats with experimental allergic encephalomyelitis. J Neural Transm 104:399-417.
36. Scarisbrick IA, Isackson PJ, Windebank AJ. 1997a. Differential tissue and developmental expression of a novel serine protease. Soc Neurosci Abs 23:33.9.
37. Scarisbrick IA, Towner MD, Isackson PJ. 1997b. Nervous system specific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci 17:8156-8168.
38. Scarisbrick IA, Isackson PJ, Windebank AJ. 1999. Differential expression of BDNF, NT-3 and NT-4/5 in the adult rat spinal cord: regulation by the glutamate receptor agonist KA. J Neurosci 18:7757-7769
39. Scherer SS, Braun PE, Grinspan J, Collarini E, Wang D-Y, Kamholz J. 1994. Differential regulation of the 2′,3′-cyclic nucleotide 3′-phosphodiesterase gene during oligodendrocyte development. Neuron 12:1363-1375.
40. Seeds N, Haffke S, Christensen K, Schoonmaker J. 1990. Cerebellar granule cell migration involves proteolysis. Adv Exp Med Biol 265: 169-178.
41. Seeds NW, Verrall S, Friedman G, Hayden S, Gadotti D, Haffke S, Christensen K, Gardner B, McGuire P, Krystosek A. 1992. Plasminogen activators and plasminogen activator inhibitors in neural development. Ann NY Acad Sci 667:32-40.
42. Seeds NW, Williams BL, Bickford PC. 1995. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 270:1992-1994.
43. Smith ME. 1980. Protease inhibitors and the suppression of EAE. In: Davison AN, Cuzner ML, editors. The suppression of experimental allergic encephalomyelitis and multiple sclerosis. San Diego, CA: Academic Press. p 211-226.
44. Smith ME, Amaducci LA. 1982. Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis. J Neurochem Res 7:541-554.
45. Suidan HS, Stone SR, Hemmings BA, Monard D. 1992. Thrombin causes neurite retraction in neuronal cells through activation of cell surface receptors. Neuron 8:363-375.
46. Tsirka SE, Gualandris A, Amaral DG, Strickland S. 1995. Excitotoxin induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377:340-344.
47. Tsirka SE, Rogove AD, Strickland S. 1996. Tissue plasminogen activator and neuronal cell death. Nature 384:124-124.
48. Tsirka SE, Rogove AD, Bugge TH, Degan JL, Strickland S. 1997. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 15:543-552.
49. Valinsky J, Le Douarin N. 1985. Production of plasminogen activator by migrating cephalic neural crest cells. EMBO J 4:1403-1406.
50. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson P-B, Stabler G, Miller K. 1999. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Am Acad Neurol 53:1397-1401.
51. Yu WP, Collarini EJ, Pringle NP, Richardson WD. 1994. Embryonic expression of myelin genes: evidence for a focal source of oligodendrocyte precursors in the ventricular zone of the neural tube. Neuron 12:1353-1362.